Comments

Cullinan Therapeutics Stock Price, Quotes and Forecasts

Q: What sector and industry does Cullinan Therapeutics (CGEM) operate in?

Cullinan Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

CGEMNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

Cullinan Therapeutics (CGEM) Forecast

News Earnings Cullinan Therapeutics (CGEM) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Cullinan Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:CGEM | Benzinga

Explore Cullinan Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for CGEM.

Open	$8.25
Close	-
Volume / Avg.	76.60K / 472.14K
Day Range	$8.05 - $8.49
52 Wk Range	7.90 - 30.19
Market Cap	$473.37M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	36
Short Interest	17.17%
Days to Cover	19.35

Recent News

MicroStrategy, Portland General Electric And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Thursday.

Avi Kapoor

Adobe, Keros Therapeutics, Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Avi Kapoor

Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market

Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent dosing benefits.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Oct 24

Jan

Feb

Mar

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$8.25
Close	-
Volume / Avg.	76.60K / 472.14K
Day Range	$8.05 - $8.49
52 Wk Range	7.90 - 30.19
Market Cap	$473.37M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	36
Short Interest	17.17%
Days to Cover	19.35

About Cullinan Therapeutics Inc

Sector

Health Care

Industry

Biotechnology

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Cullinan Therapeutics (CGEM) stock?

You can purchase shares of Cullinan Therapeutics (NASDAQ:CGEM) through any online brokerage.

View our list of the best stock brokerages

Who are Cullinan Therapeutics (CGEM) competitors?

Other companies in Cullinan Therapeutics’s space includes: Valneva (NASDAQ:VALN), Precigen (NASDAQ:PGEN), Altimmune (NASDAQ:ALT), Immatics (NASDAQ:IMTX) and Sage Therapeutics (NASDAQ:SAGE).

What is the forecast, or price target, for Cullinan Therapeutics (CGEM) stock?

Cullinan Therapeutics has a consensus price target of $31.88.

What is the current price for Cullinan Therapeutics (CGEM)?

The stock price for Cullinan Therapeutics (NASDAQ: CGEM) is $8.09 last updated March 26, 2025 at 10:14 AM EDT.

Does Cullinan Therapeutics (CGEM) pay a dividend?

There are no upcoming dividends for Cullinan Therapeutics.

When is Cullinan Therapeutics (NASDAQ:CGEM) reporting earnings?

Cullinan Therapeutics’s Q1 earnings are confirmed for Wednesday, May 14, 2025.

Is Cullinan Therapeutics (CGEM) going to split?

There is no upcoming split for Cullinan Therapeutics.

What sector and industry does Cullinan Therapeutics (CGEM) operate in?

Cullinan Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.